SABR Combats Metastatic Disease.
Stereotactic ablative radiotherapy may improve survival of patients with metastatic disease. In a phase II trial, patients with a small number of metastases due to breast, colorectal, prostate, and lung cancers who were treated with the therapy had longer overall and progression-free survival than patients who received standard-of-care palliative radiation therapy.